Navigation Links
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Date:2/11/2013

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188.  

Brian M. Culley , Chief Executive Officer, said: "Consistent with our guidance from October 2011 and our commitment to FDA, we have initiated this study before the end of the first quarter.  We were pleased with the discussion we had with the Agency on the study protocol and our agreement on the supra-therapeutic dose." 

Santosh Vetticaden, Chief Medical Officer, said: "The FDA requires an assessment of cardiac repolarization for most new drugs having systemic bioavailability. This study will assess whether or not ANX-188 has an effect on QT prolongation. The study should complete dosing in the first quarter, and we expect to announce results in the second quarter of 2013."

The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers.  The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial.  Sixty subjects will be enrolled.  Each subject will receive each of four treatments (placebo, active control, ANX-188 therapeutic dose, ANX-188 supra-therapeutic dose) during each of the four treatment periods.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions.  The C
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Establishment of Regulatory Advisory Board
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
5. Applied Genetics Initiates Commercial Operation
6. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
10. Positive Clinical Study Results for BSPs HyperQ Technology
11. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... G-CON Manufacturing Inc., the standard in design and ... leadership appointment designed to drive the company’s ambitious growth ... Maik Jornitz, Chief Operating Officer of G-Con Manufacturing, has ... the pioneering company through its next phase of market ... and look forward to providing our next generation of ...
(Date:7/29/2014)... July 29, 2014 White papers ... and cloud based eClinical technologies, have been published by ... These follow a long line of white papers by ... including Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , ... a paper by CTO Marc Desgrousilliers, 'The Five ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The Workgroup ... authority on the use of health IT to create ... Health Plan Identifier (HPID) Workgroup has developed an ... Health Plan and Payer?” The HPID Workgroup, a part ... with the Centers for Medicare and Medicaid Services (CMS) ...
Breaking Biology Technology:Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2
... Ind., Jan. 23 Zimmer Holdings, Inc.,(NYSE: ZMH ... announced,today it will be participating in the Wachovia Securities ... 10:15 a.m. Eastern Time., A live webcast of ... at http://investor.zimmer.com . The webcast will,be archived for ...
... QED International Associates, Inc.,administrator for the HealthShares(TM) ... HealthShares(TM) Exchange-Traded Funds, today announced,that effective at the ... Pharmaceuticals Inc. (Nasdaq: REGN ) will replace ... HealthShares(TM) Composite Index. MGI Pharma is being,acquired by ...
... 23 /PRNewswire/ - Dalton Medicinal Chemistry Partners,the ... announces that it,has achieved another targeted milestone ... (Canada) Ltd., Dalton Medicinal Chemistry Partners ... and synthesize novel compounds against an,antiviral target ...
Cached Biology Technology:QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes 2
(Date:7/29/2014)... that brings together two of the major disciplines behind ... insect fossils through stunning photographs and unique illustrations. , ... Jepson, details the incredible preservation and diversity of fossilised ... what these remarkable fossils can tell us about the ... our planet. Like the mosquito in Jurassic Park, many ...
(Date:7/28/2014)... new discovery of two additional coral communities showing signs of ... footprint of the 2010 spill in the Gulf of Mexico. ... Fisher, professor of biology at Penn State University. A paper ... corals in the Gulf of Mexico will be published during ... Edition of the journal Proceedings of the National Academy ...
(Date:7/28/2014)... John Essigmann and colleagues from the University of Washington had ... they could induce the virus to mutate uncontrollably, they could ... strategy that our immune system uses against many viruses. ... to mutate at an enhanced rate, as expected. But it ... clinical trial reported in 2011. In a new study, however, ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4
... have experienced rotator cuff tears are at increased risk of ... the May 2009 issue of The Journal of Bone ... genetic predisposition as a possible cause for rotator cuff disease," ... University of Utah School of Medicine Orthopaedic Center in Salt ...
... of scientists from Canada, Spain and the United States has ... against environmental stresses like drought, freezing and heat. ... signal adverse conditions and help them adapt," says team member ... the University of Toronto. "If we can control these ...
... cleared tens of thousands of square miles of forests to ... popular food ingredient. Ancient peatlands have been drained and lush ... landscape of equatorial Asia now lies vulnerable to fires, which ... the air as well as the land. A team ...
Cached Biology News:Rotator cuff tears: Are they all in the family? 2International team finds key gene that allows plants to survive drought 2NASA study says climate adds fuel to Asian wildfire emissions 2NASA study says climate adds fuel to Asian wildfire emissions 3NASA study says climate adds fuel to Asian wildfire emissions 4
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
SAPK/JNK Antibody...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Biology Products: